Comparing a new CAR-T therapy to standard treatments for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have multiple myeloma that has gotten worse during or after your last treatment.
- You must have received 1 to 3 prior treatments, including at least one immunomodulatory drug and either a proteasome inhibitor or a CD38 antibody.
- You must have measurable disease, such as certain protein levels in blood or urine.
- You must be able to receive one of the standard chemotherapy combinations used in this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests AZD0120 in people with multiple myeloma that has come back or is not responding to treatment. It may help by targeting the myeloma cells after you’ve already tried several standard therapies.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial tests two new CAR-T cell therapies (LCAR-M61S and LCAR-M61D) for people whose multiple myeloma has come back or stopped responding to at least three prior treatments. The treatment uses your own immune cells that are modified to find and attack cancer cells.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.
This trial tests an investigational CAR-T cell therapy (anitocabtagene autoleucel) in people with newly diagnosed multiple myeloma. It aims to see if this treatment is safe and effective when given after a short course of standard chemotherapy.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.